首页> 美国卫生研究院文献>Journal of Translational Medicine >Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)

【2h】

Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)

机译：结合靶向治疗和免疫治疗：BRAF抑制剂dabrafenib（D）±MEK抑制剂曲美替尼（T）与ipilimumab（Ipi）联合治疗V600E / K突变阳性的不可切除或转移性黑色素瘤（MM）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Journal of Translational Medicine
作者
Igor Puzanov;
展开▼
作者单位

展开▼
年(卷),期 2015(13),Suppl 1
年度 2015
页码 K8
总页数 2
原文格式 PDF
正文语种
中图分类医学史;
关键词

相似文献

外文文献
中文文献
专利

1. Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) [J] . Igor Puzanov Journal of Translational Medicine . 2015,第SUPPLEMENTa1期

机译：结合靶向治疗和免疫治疗：BRAF抑制剂dabrafenib（D）±MEK抑制剂曲美替尼（T）与ipilimumab（Ipi）联合治疗V600E / K突变阳性的不可切除或转移性黑色素瘤（MM）
2. Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy [J] . Caitlyn N. Myrdal, Srinath Sundararajan Case Reports in Oncological Medicine . 2020,第3期

机译：对Ipilimumab / Nivolumab重新检查和BRAF抑制剂/ MEK抑制剂在患者中重新检查，所述患者预先用BRAF靶向治疗和免疫治疗治疗
3. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4 [J] . Liu Li, Mayes Patrick A., Eastman Stephen, Clinical cancer research: an official journal of the American Association for Cancer Research . 2015,第7期

机译：BRAF和MEK抑制剂Dabrafenib和Trametinib：对免疫功能的影响以及与靶向PD-1，PD-L1和CTLA-4的免疫调节抗体的组合
4. Gene Expression Models of BRAF Inhibitor Resistance in Melanoma Predict Drug Repurposing Candidates for Novel Combination Therapies [C] . Kelly Regan, Andrew R. Stiff, William E. Carson, International Molecular Medicine Tri-Conference. . 2016

机译：黑色素瘤中BRAF抑制剂抗性的基因表达模型预测了新型组合疗法的药物重新培养候选者
5. Optimizing MEK Inhibitors in NRAS Mutant Melanoma - Overcoming Resistance and Combination Strategies [D] . Nguyen, Mai. 2021

机译：优化NRAS突变体黑素瘤耐久性和组合策略中的MEK抑制剂
6. Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy [O] . Caitlyn N. Myrdal, Srinath Sundararajan 2020

机译：对Ipilimumab / Nivolumab重新检查和BRAF抑制剂/ MEK抑制剂在患者中重新检查所述患者预先用BRAF靶向治疗和免疫治疗治疗
7. Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) [O] . 2015

机译：结合靶向治疗和免疫治疗：BRAF抑制剂dabrafenib（D）±MEK抑制剂曲美替尼（T）与ipilimumab（Ipi）联合治疗V600E / K突变阳性的不可切除或转移性黑色素瘤（MM）

Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)

著录项

相似文献

相关主题

期刊订阅